ADMA Biologics (ADMA) PT Lowered to $18 at Canaccord

May 7, 2026 6:38 AM

Canaccord analyst Gary Nachmann lowered the price target on ADMA Biologics (NASDAQ: ADMA) to $18.00 (from $21.00) while maintaining a Buy rating.

No results found